Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 2, 2010, Pages 111-115

  Chen, Yaoyu ^a   Peng, Cong ^a   Sullivan, Con ^b   Li, Dongguang ^c   Li, Shaoguang ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Maine Institute of Human Genetics and Health   (United States)

^c EDITH COWAN UNIVERSITY   (Australia)

Author keywords

BCR ABL; CML; Leukemic stem cells; Therapeutic agents

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANSAMYCIN DERIVATIVE; ARACHIDONATE 5 LIPOXYGENASE; BCR ABL PROTEIN; BETA CATENIN; BIM PROTEIN; BRYOSTATIN 1; CASPASE 3; CASPASE 9; CD34 ANTIBODY; CYCLIN A; CYCLOPAMINE; DASATINIB; GDC 0449; GELDANAMYCIN; GENE PRODUCT; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; OMACETAXINE; PROTEIN INHIBITOR; PROTEIN KINASE C BETA; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; SONIC HEDGEHOG PROTEIN; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; WNT PROTEIN; ZILEUTON;

CANCER STEM CELL; CANCER THERAPY; CELL DIFFERENTIATION; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GENE CONTROL; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKOCYTE COUNT; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; TARGET CELL;

EID: 77950840705     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010790909326     Document Type: Review

References (45)

1. Bartram, C.R.; de Klein, A.; Hagemeijer, A.; van Agthoven, T.; Geurts van Kessel, A.; Bootsma, D.; Grosveld, G.; Ferguson-Smith, M.A.; Davies, T.; Stone, M. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature, 1983, 306(5940), 277-280.
2. Deininger, M.W.; Goldman, J.M.; Melo, J.V. The molecular biology of chronic myeloid leukemia. Blood, 2000, 96(10), 3343-3356.
3. Pane, F.; Frigeri, F.; Sindona, M.; Luciano, L.; Ferrara, F.; Cimino, R.; Meloni, G.; Saglio, G.; Salvatore, F.; Rotoli, B. Neutrophilicchronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood, 1996, 88(7), 2410-2414.
4. Sattler, M.; Griffin, J.D. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin. Hematol., 2003, 40(2 Suppl 2), 4-10.
5. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344(14), 1031-1037.
6. Bhatia, R.; Holtz, M.; Niu, N.; Gray, R.; Snyder, D.S.; Sawyers, C.L.; Arber, D.A.; Slovak, M.L.; Forman, S.J. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 2003, 101(12), 4701-4707.
7. Graham, S.M.; Jorgensen, H.G.; Allan, E.; Pearson, C.; Alcorn, M.J.; Richmond, L.; Holyoake, T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 2002, 99(1), 319-325.
8. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414(6859), 105-111.
9. Jordan, C.T.; Guzman, M.L.; Noble, M. Cancer stem cells. N. Engl. J. Med., 2006, 355(12), 1253-1261.
10. Pardal, R.; Clarke, M.F.; Morrison, S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev., 2003, 3(12), 895-902.
11. Rossi, D.J.; Jamieson, C.H.; Weissman, I.L. Stems cells and the pathways to aging and cancer. Cell, 2008, 132(4), 681-696.
12. Wang, J.C.; Dick, J.E. Cancer stem cells: lessons from leukemia. Trends Cell Biol., 2005, 15(9), 494-501.
13. Hu, Y.; Swerdlow, S.; Duffy, T.M.; Weinmann, R.; Lee, F.Y.; Li, S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc. Natl. Acad. Sci. USA, 2006, 103(45), 16870-16875.
14. Hu, Y.; Chen, Y.; Douglas, L.; Li, S. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia, 2009, 23(1), 109-116.
15. Dierks, C.; Beigi, R.; Guo, G.R.; Zirlik, K.; Stegert, M.R.; Manley, P.; Trussell, C.; Schmitt-Graeff, A.; Landwerlin, K.; Veelken, H.; Warmuth, M. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell, 2008, 14(3), 238-249.
16. Zhao, C.; Blum, J.; Chen, A.; Kwon, H.Y.; Jung, S.H.; Cook, J.M.; Lagoo, A.; Reya, T. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell, 2007, 12(6), 528-541.
17. Lessard, J.; Sauvageau, G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature, 2003, 423(6937), 255-260.
18. Catalano, A.; Rodilossi, S.; Caprari, P.; Coppola, V.; Procopio, A. 5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation. EMBO J., 2005, 24(1), 170-179.
19. Chen, X.S.; Sheller, J.R.; Johnson, E.N.; Funk, C.D. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature, 1994, 372(6502), 179-182.
20. Radmark, O.; Werz, O.; Steinhilber, D.; Samuelsson, B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci., 2007, 32(7), 332-341.
21. Graham, S.M.; Vass, J.K.; Holyoake, T.L.; Graham, G.J. Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells (Dayton, Ohio), 2007, 25(12), 3111-3120.
22. Radich, J.P.; Dai, H.; Mao, M.; Oehler, V.; Schelter, J.; Druker, B.; Sawyers, C.; Shah, N.; Stock, W.; Willman, C.L.; Friend, S.; Linsley, P.S. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl .Acad. Sci. USA, 2006, 103 (8), 2794-2799.
23. Anderson, K.M.; Seed, T.; Plate, J.M.; Jajeh, A.; Meng, J.; Harris, J.E. Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Leuk. Res., 1995, 19(11), 789-801.
24. Chen, Y.; Hu, Y.; Zhang, H.; Peng, C.; Li, S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet., 2009, 41(7), 783-792.
25. Knapp, H.R. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N. Engl. J. Med., 1990, 323(25), 1745-1748.
26. Scheibel, T.; Buchner, J. The Hsp90 complex--a super-chaperone machine as a novel drug target. Biochem. Pharmacol., 1998, 56(6), 675-682.
27. Solit, D.B.; Zheng, F.F.; Drobnjak, M.; Munster, P.N.; Higgins, B.; Verbel, D.; Heller, G.; Tong, W.; Cordon-Cardo, C.; Agus, D.B.; Scher, H.I.; Rosen, N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res., 2002, 8(5), 986-993.
28. Whitesell, L.; Mimnaugh, E.G.; De Costa, B.; Myers, C.E.; Neckers, L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 1994, 91(18), 8324-8328.
29. An, W.G.; Schulte, T.W.; Neckers, L.M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ., 2000, 11(7), 355-360.
30. Nimmanapalli, R.; O'Bryan, E.; Bhalla, K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Ablpositive human leukemic blasts. Cancer Res., 2001, 61(5), 1799-1804.
31. Ge, J.; Normant, E.; Porter, J.R.; Ali, J.A.; Dembski, M.S.; Gao, Y.; Georges, A.T.; Grenier, L.; Pak, R.H.; Patterson, J.; Sydor, J.R.; Tibbitts, T.T.; Tong, J.K.; Adams, J.; Palombella, V.J. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J. Med. Chem., 2006, 49(15), 4606-4615.
32. Gorre, M.E.; Ellwood-Yen, K.; Chiosis, G.; Rosen, N.; Sawyers, C.L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90 .Blood, 2002, 100(8), 3041-3044.
33. Peng, C.; Brain, J.; Hu, Y.; Goodrich, A.; Kong, L.; Grayzel, D.; Pak, R.; Read, M.; Li, S. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood, 2007, 110(2), 678-685.
34. Kantarjian, H.M.; Talpaz, M.; Santini, V.; Murgo, A.; Cheson, B.; O'Brien, S.M. Homoharringtonine: history, current research, and future direction. Cancer, 2001, 92(6), 1591-1605.
35. Luo, C.Y.; Tang, J.Y.; Wang, Y.P. Homoharringtonine: a new treatment option for myeloid leukemia. Hematololy, 2004, 9(4), 259-270.
36. Quintas-Cardama, A.; Kantarjian, H.; Garcia-Manero, G.; O'Brien, S.; Faderl, S.; Estrov, Z.; Giles, F.; Murgo, A.; Ladie, N.; Verstovsek, S.; Cortes, J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer, 2007, 109(2), 248-255.
37. Chen, Y.; Hu, Y.; Michaels, S.; Segal, D.; Brown, D.; Li, S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABLinduced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia, 2009, 23 (8), 1446-1454.
38. Legros, L.; Hayette, S.; Nicolini, F.E.; Raynaud, S.; Chabane, K.; Magaud, J.P.; Cassuto, J.P.; Michallet, M. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia, 2007, 21(10), 2204-2206.
39. Taipale, J.; Beachy, P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature, 2001, 411 (6835), 349-354.
40. Zhao, C.; Chen, A.; Jamieson, C.H.; Fereshteh, M.; Abrahamsson, A.; Blum, J.; Kwon, H.Y.; Kim, J.; Chute, J.P.; Rizzieri, D.; Munchhof, M.; VanArsdale, T.; Beachy, P.A.; Reya, T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature, 2009, 458(7239), 776-779.
41. Chen, J.K.; Taipale, J.; Cooper, M.K.; Beachy, P.A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev., 2002, 16 (21), 2743-2748.
42. Dlugosz, A.A.; Talpaz, M. Following the hedgehog to new cancer therapies. N. Engl. J. Med., 2009, 361(12), 1202-1205.
43. Manne, V.; Lee, F.Y.; Bol, D.K.; Gullo-Brown, J.; Fairchild, C.R.; Lombardo, L.J.; Smykla, R.A.; Vite, G.D.; Wen, M.L.; Yu, C.; Wong, T.W.; Hunt, J.T. Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models. Cancer Res., 2004, 64(11), 3974-3980.
44. Pellicano, F.; Copland, M.; Jorgensen, H.G.; Mountford, J.; Leber, B.; Holyoake, T.L. BMS-214662 induces mitochondrial apoptosis in CML stem/progenitor cells, including CD34+38- cells, through activation of protein kinase C{beta}. Blood, 2009, 114(19), 4186-4196.
45. Copland, M.; Pellicano, F.; Richmond, L.; Allan, E.K.; Hamilton, A.; Lee, F.Y.; Weinmann, R.; Holyoake, T.L. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood, 2008, 111(5), 2843-2853.